A Phase 1, Open-label, Trial of the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 Following a Single Oral Dose in Healthy Male Participants
Mirum Pharmaceuticals, Inc.
Summary
This is a Phase 1, open label study in healthy male participants to study the Absorption, Distribution, Metabolism, and Excretion of \[14C\]-MRM-3379 drug following a single oral dose.
Eligibility
- Age range
- 18–55 years
- Sex
- Male
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Male of any race, between 18 and 55 years of age, inclusive. 2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a body weight between 50 and 110 kg, inclusive. 3. In good health, as determined by medical history, and as assessed by the investigator (or designee). 4. Able to comprehend and are willing to sign the ICF and abide by the trial restrictions. Exclusion Criteria: 1. History of or current medical condition that would place the participant at risk from study participation. 2. Administration of any vaccine within 30 days prior to dosing. 3. Use or in…
Interventions
- Drug[14C]-MRM-3379
Oral capsule administered on Day 1 only.
Location
- Fortrea Clinical Research Unit IncMadison, Wisconsin